TCI Wealth Advisors’s Humacyte HUMA Stock Holding History

TCI Wealth Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,557	Closed	-$4.81K	–	1112
2023 Q1	$4.81K	Buy	+1,557	New	+$4.43K	﹤0.01%	1559

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

TCI Wealth Advisors's HUMA Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Humacyte (HUMA) in Q2 2023, closing a stake of 1,557 shares — an estimated $4.81K sold.

TCI Wealth Advisors first reported a position in HUMA in Q1 2023 and held it in 1 quarter. The position peaked at $4.81K in Q1 2023. 75 funds tracked by Wall St. Rank hold HUMA as of Q2 2023.

TCI Wealth Advisors reported no remaining Humacyte position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 1,557 Humacyte shares in Q2 2023, an estimated $4.81K.
TCI Wealth Advisors first reported a position in Humacyte in Q1 2023 and held it in 1 quarter.
TCI Wealth Advisors's Humacyte position peaked at $4.81K in Q1 2023.
75 funds tracked by Wall St. Rank held Humacyte as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.